A Phase 1, Double-blind, Placebo-controlled, Randomized, Single and Multiple Ascending Dose, and a Japanese Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986172, Including an Open-Label Assessment of Relative Bioavailability and Food Effect on the Single-Dose Pharmacokinetics of BMS-986172 in Healthy and Obese Otherwise Healthy Participants
Latest Information Update: 07 Jun 2022
At a glance
- Drugs BMS-986172 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 02 Jun 2022 Status changed from active, no longer recruiting to completed.
- 18 Feb 2022 Status changed from not yet recruiting to active, no longer recruiting.
- 18 Jun 2021 New trial record